Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 76,3% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Novavax NVAX

Novavax live grafieken

Inzichten

Weekly Search
Weekly
Daily
date Sluit change % verandering Openen Piek Bodem

Markets.com news

New Zealand dollar drops on unexpected dovish tone from RBNZ
Georgy Istigechev 2024 Jul 10, 10:00

Unexpected dovish tone from RBNZ drops New Zealand dollar

Forex Indices USD
Sterling steady as investors take in UK, French election results
Georgy Istigechev 2024 Jul 09, 10:15

Sterling steady near one-month high in wake of UK election

Forex Indices GBP USD EUR
BP shares fall on Q2 profit warning
Georgy Istigechev 2024 Jul 09, 10:00

BP shares drop over 4% on Q2 lower profit warning

Shares Indices Oil FTSE100
BP shares dip ahead of Powell Congress testimony
Neil Wilson 2024 Jul 09, 07:30

BP dips, Powell Congress speech ahead, records for Tokyo, NY

Shares Indices Forex Commodities

Info

Spread

0.07

Spread (%)

0.7609 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt gesloten

Dinsdag

14:31 - 20:59

Maandag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

Vrijdag

14:31-20:59

Inkomstenverklaring

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

1383998336

Uitstaande aandelen

160184992

Datum winstcijfer (volgende)

2019-05-10

instr__dividend_date

2019-05-10

instr__ex_dividend_date

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

Winst per aandeel

-2.18

Uitstaande aandelen

Novavax Novavax Inc
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Meer informatie over dit instrument

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat